Multicenter observational study of fulvestrant 500 mg in postmenopausal Japanese women with ER positive advanced or recurrent breast cancer after prior endocrine treatment (SBCCSG29 study)

被引：0
|
作者：
Kimizuka, K. [1 ]
Inoue, K. [2 ]
Nagai, S. [2 ]
Saito, T. [3 ]
Nakano, S. [4 ]
Futsuhara, K. [5 ]
Sakurai, T. [6 ]
Yamada, H. [7 ]
Hata, S. [8 ]
Kaneko, S. [9 ]
Kurosumi, M. [10 ]
机构：
[1] Kasukabe Municipal Hosp, Dept Breast Surg, Kasukabe, Japan
[2] Saitama Canc Ctr, Dept Breast Oncol, Saitama, Japan
[3] Saitama Red Cross Hosp, Dept Breast Surg, Saitama, Japan
[4] Kawaguchi Municipal Med Ctr, Dept Surg, Kawaguchi, Japan
[5] Jichi Med Univ, Saitama Med Ctr, Div Breast Oncol, Dept Surg, Saitama, Japan
[6] JCHO Saitama Med Ctr, Dept Surg, Saitama, Japan
[7] Sekishindo Hosp, Dept Surg, Kawagoe, Saitama, Japan
[8] Mitsui Hosp, Dept Breast Surg, Kawagoe, Saitama, Japan
[9] Saitama Cooperat Hosp, Dept Surg, Kawaguchi, Saitama, Japan
[10] Saitama Canc Ctr, Dept Pathol, Saitama, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
57PD
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [21] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer (vol 28, pg 4594, 2010)
    Di Leo, A.
    Jerusalem, G.
    Petruzelka, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2293 - 2293
  • [22] Quality of life and symptom treatment response in postmenopausal women with advanced breast cancer (ABC) receiving Fulvestrant after progression on prior antiestrogen therapy
    Kalyadina, S.
    Novik, A.
    Ionova, T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 195 - 195
  • [23] A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the
    Jiang, Zefei
    Zhang, Qingyuan
    Shao, Zhimin
    Shen, Kunwei
    Li, Li
    Feng, Jifeng
    Tong, Zhongseng
    Gu, Kangsheng
    Wang, Xiaojia
    Xu, Binghe
    Sun, Guofang
    Chen, Huifang
    Rukazenkov, Yuri
    CANCER RESEARCH, 2015, 75
  • [24] A multicenter study of pre-operative treatment with Femara® (Letrozole) for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer.
    Paepke, S
    Bouterfa, H
    Wallwiener, D
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 290 - 290
  • [25] A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer
    Hirata, Taizo
    Ozaki, Shinji
    Tabata, Masahiro
    Iwamoto, Takayuki
    Hinotsu, Shiro
    Hamada, Akinobu
    Motoki, Takayuki
    Nogami, Tomohiro
    Shien, Tadahiko
    Taira, Naruto
    Matsuoka, Junji
    Doihara, Hiroyoshi
    INTERNAL MEDICINE, 2021, 60 (08) : 1183 - 1190
  • [26] A randomized phase II trial of toremifene (120 mg) versus fulvestrant ( 500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study)
    Nishimura, Reiki
    Yamamoto, Yutaka
    Narui, Kazutaka
    Kijima, Yuko
    Hozumi, Yasuo
    Ikeda, Masahiko
    Takao, Shintaro
    Ohtani, Shoichiro
    Iwase, Hirotaka
    CANCER RESEARCH, 2018, 78 (04)
  • [27] A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). "The FLIPPER study" (GEICAM/2014-12)
    Moreno, F.
    Martinez-Janez, N.
    Garau, I.
    Guerra, J. A.
    Alarcon, J.
    Bermejo, B.
    Gonzalez-Cortijo, L.
    Bueno, C.
    Lao, J.
    Bezares, S.
    Rosell, L.
    Blanch, A.
    Caballero, R.
    Carrasco, E.
    Rojo, F.
    Martin, M.
    O'Connor, M.
    Hernando, A.
    Albanell, J.
    CANCER RESEARCH, 2017, 77
  • [28] A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer
    Robertson, J. F. R.
    Zefei, J.
    Di Leo, A.
    Ohno, S.
    Pritchard, K. I.
    Ellis, M.
    Bradbury, I.
    Campbell, C.
    CANCER RESEARCH, 2016, 76
  • [29] Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer
    Lindemann, J. P. O.
    Robertson, J. F. R.
    Ellis, M. J.
    Menu, Y.
    Macpherson, E. J.
    Ghiorghiu, D. D. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 282 - 282
  • [30] Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)
    Kawaguchi, H.
    Masuda, N.
    Nakayama, T.
    Aogi, K.
    Anan, K.
    Ito, Y.
    Ohtani, S.
    Sato, N.
    Saji, S.
    Tokunaga, E.
    Nakamura, S.
    Hasegawa, Y.
    Hattori, M.
    Fujisawa, T.
    Morita, S.
    Yamaguchi, M.
    Yamashita, T.
    Yamamoto, Y.
    Ohno, S.
    Toi, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S109 - S109
12345